20:05 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Proteostasis sinks after Phase I data for CF triplet therapy

Proteostasis lost $2.76 (68%) to $1.31 on Monday after reporting Phase I data for its triplet cystic fibrosis therapy that lagged behind Phase III data of triple combination CF therapies from Vertex. Proteostasis Therapeutics Inc....
21:04 , Mar 27, 2019 |  BC Extra  |  Company News

Expired Orkambi could have treated over 600 patients in 2018

Vertex destroyed almost 8,000 expired packs of cystic fibrosis drug Orkambi lumacaftor/ivacaftor that were stocked in the U.K. last year, according to a letter from Simon Lem, the company's VP & and general manager, Northern...
20:31 , Mar 6, 2019 |  BC Extra  |  Clinical News

Ahead of House of Commons meeting, another Vertex triple CF combo meets in Phase III

A day before Parliament's House of Commons Health and Social Care Committee is scheduled to hold a public hearing on the availability and pricing of Vertex's portfolio of cystic fibrosis drugs, the biotech announced that...
19:38 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Vertex's tezacaftor/ivacaftor meets in Phase III for pediatric CF

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said tezacaftor/ivacaftor met the primary endpoint of improving the absolute change in lung clearance index in a double-blind, European and Australian Phase III trial to treat children with cystic fibrosis. In...
22:03 , Feb 15, 2019 |  BC Extra  |  Politics & Policy

NICE provides first scientific advice on patient preference

The National Institute for Health and Care Excellence said on Thursday that it provided its first scientific advice to Novartis AG (NYSE:NVS; SIX:NOVN) on the design of a patient preference study for chronic obstructive pulmonary...
17:50 , Feb 13, 2019 |  BC Week In Review  |  Company News

Vertex gets Priority Review voucher from Symdeko approval

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it received a Priority Review voucher on Jan. 29 from FDA based on the February 2018 approval of Symdeko tezacaftor/ivacaftor to treat cystic fibrosis in patients ages 12 and older....
18:57 , Feb 7, 2019 |  BC Week In Review  |  Company News

MPs question cost of an Orkambi compulsory license

Parliamentary Under-Secretary for Health and Social Care Steve Brine said a compulsory license for cystic fibrosis drug Orkambi ivacaftor/lumacaftor could cost NHS England more in the long run than negotiating a deal with Vertex Pharmaceuticals...
00:50 , Feb 5, 2019 |  BC Extra  |  Politics & Policy

MPs question cost of an Orkambi compulsory license

Parliamentary Under-Secretary for Health and Social Care Steve Brine said a compulsory license for cystic fibrosis drug Orkambi ivacaftor/lumacaftor could cost NHS England more in the long run than negotiating a deal with Vertex Pharmaceuticals...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
20:44 , Dec 21, 2018 |  BC Week In Review  |  Company News

U.K. committee releases Orkambi documents; pricing details lacking

As NICE, NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) remain at an impasse over the pricing of cystic fibrosis drug Orkambi ivacaftor/lumacaftor, a U.K. parliamentary committee made good on its promise on Dec. 20, releasing...